Publications by authors named "G Sabella"
Background: In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit from chemotherapy. Immunotherapy may eliminate the need for chemotherapy or surgery.
Patients And Methods: INFINITY is a multicenter, multicohort phase II trial (NCT04817826) investigating in cohort 1 the activity and safety of tremelimumab + durvalumab (T300/D) as neoadjuvant treatment of mismatch repair deficient/MSI-H, resectable gastric/gastroesophageal junction adenocarcinoma.
Purpose: Novel combinations are required to overcome resistance to immune checkpoint inhibitors (ICIs) in proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC). We aimed to determine whether vorbipiprant, a prostaglandin EP4 receptor antagonist, can convert immune-resistant mCRC into a tumor responsive to anti-PD-1 inhibition.
Patients And Methods: This phase 1b/2a prospective, open-label, single-arm trial followed a 3 + 3 dose escalation and dose optimization design.
Article Synopsis
- * The study tested the effects of three natural compounds—quercetin (QER), epigallocatechin gallate (EGG), and fisetin (FIS)—on patient-derived organoids (PDOs) obtained from polyps, assessing their impact on cell growth and apoptosis.
- * Fisetin (FIS) was the most effective compound in inducing cell death in the organoid models, suggesting that diets rich in these compounds could serve as a supplementary strategy to reduce CRC risk in FAP
Article Synopsis
- Colorectal cancer (CRC) is linked to factors like obesity and inflammation, which may disrupt immune response by accumulating foam cells (FC) in tumors, potentially impacting cancer progression.*
- The study involved analyzing tumor samples from CRC patients to investigate the relationship between FC and immune cell dynamics, highlighting the presence of reduced CD8 T cells and increased regulatory T cells in tumors with high FC accumulation.*
- Results indicated that higher levels of FC are associated with worse outcomes, including lower disease-free survival rates in CRC, and in vitro experiments showed that FC suppress CD8 T cell activity through mechanisms involving TGF-β.*
Background: Rectal neuroendocrine tumors (rNENs) are rare, constituting 1-2% of rectal tumors, and are often asymptomatic, leading to challenges in early diagnosis. Current management guidelines recommend endoscopic resection for small lesions and surgical intervention for larger or high-risk tumors. This study aims to retrospectively analyze the pathological characteristics, management, and prognosis of rNEN patients.
View Article and Find Full Text PDF